Advanced searches left 3/3

ACE Inhibitor - Europe PMC

Summarized by Plex Scholar
Last Updated: 10 April 2022

* If you want to update the article please login/register

Beta-blocker/ACE inhibitor therapy differentially impacts the steady state signaling landscape of failing and non-failing hearts.

Combination therapy with angiotensin-converting enzyme inhibitors and -adrenergic receptor blockers is also used as a therapy for non-cardiac conditions in heart failure with reduced ejection fraction. In cardiac left ventricles, we used proteomics and phosphorylation techniques to map global changes in protein availability and phosphorylation state as a result of combination therapy of -AR blocker and ACE inhibitor in HFrEF and control hearts. The finding of divergent signaling outcomes depending on disease state underlines the importance of investigating drug effects within the context of the recipient heart's unique conditions.

Source link: https://europepmc.org/article/MED/35306519

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions